The Increasingly Human and Profitable Monoclonal Antibody Market

被引：359

作者：

Grilo, Antonio L. ^{[1
]}

Mantalaris, A. ^{[1
]}

机构：

[1] Imperial Coll London, Dept Chem Engn, Ctr Proc Syst Engn, Biol Syst Engn Lab, Exhibit Rd, London SW7 2AZ, England

来源：

TRENDS IN BIOTECHNOLOGY | 2019年 / 37卷 / 01期

基金：

欧盟地平线“2020”;

关键词：

Molecules; -; Commerce;

D O I：

10.1016/j.tibtech.2018.05.014

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.

引用

页码：9 / 16

页数：9

共 10 条

[1] What's fueling the biotech engine-2012 to 2013 [J].

Aggarwal, Saurabh Rob .

NATURE BIOTECHNOLOGY, 2014, 32 (01) :32-39

[2] The therapeutic monoclonal antibody market [J].

Ecker, Dawn M. ;

Jones, Susan Dana ;

Levine, Howard L. .

MABS, 2015, 7 (01) :9-14

[3]

Ellis S., 2018, NATUREJOBS CAREER GU

[4] MARKET WATCH Strategies for biosimilars in emerging markets 2014 [J].

Gautam, Ajay .

NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (08) :520-+

[5] N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins [J].

Higel, Fabian ;

Seidl, Andreas ;

Soergel, Fritz ;

Friess, Wolfgang .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2016, 100 :94-100

[6] Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment [J].

Lynch, DH ;

Yang, XD .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :47-50

[7] Development trends for human monoclonal antibody therapeutics [J].

Nelson, Aaron L. ;

Dhimolea, Eugen ;

Reichert, Janice M. .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) :767-774

[8] Biopharmaceutical benchmarks 2014 [J].

Walsh, Gary .

NATURE BIOTECHNOLOGY, 2014, 32 (10) :992-1000

[9]

Wei L., 2017, CHINA BIOTECHNOL, V37, P106

[10] BiTEs: bispecific antibody constructs with unique anti-tumor activity [J].

Wolf, E ;

Hofmeister, R ;

Kufer, P ;

Schlereth, B ;

Baeuerle, PA .

DRUG DISCOVERY TODAY, 2005, 10 (18) :1237-1244

← 1 →